6-(4-甲氧苄基氨基)嘌呤 | 105945-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-(4-甲氧苄基氨基)嘌呤
• 英文名称: 6-(4-methoxybenzylamino)purine
• 英文别名: (4-methoxy-benzyl)-(7(9)H-purin-6-yl)-amine；4-MeOBap；N-[(4-methoxyphenyl)methyl]-7H-purin-6-amine
• CAS: 105945-91-3
• 化学式: C₁₃H₁₃N₅O
• 分子量: 255.279
• InChiKey: JNRWSGYVASKILI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  75.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(4-甲氧苄基氨基)嘌呤 、 copper(II) perchlorate hexahydrate 以 乙醇 为溶剂， 以36%的产率得到[Cu2(6-(4-methoxybenzylamino)purine)4(ClO4)2](ClO4)2
  参考文献：
  名称：

  Dinuclear copper(II) perchlorate complexes with 6-(benzylamino)purine derivatives: Synthesis, X-ray structure, magnetism and antiradical activity

  摘要：

  The reactions of Cu(ClO4)(2)center dot 6H(2)O with 6-(benzylamino)purine derivatives in a stoichiometric 1:2 metal-to-ligand ratio led to the formation of penta-coordinated dinuclear complexes of the formula [Cu-2(mu-L1-8)(4)(ClO4)2](ClO4)(2).nsolv, where L-1 = 6-(2-fluorobenzylamino)purine (complex 1), L-2 = 6-(3-fluorobenzylamino)purine (2), L-3= 6-(4-fluorobenzylamino)purine (3), L-4= 6-(2-chlorobenzylamino)purine (4), L-5 = 6-(3-chlorobenzylamino)purine (5), L-6=6-(4-chlorobenzylamino)purine (6), L-7= 6-(3-methoxybenzylamino)purine (7) and L-8= 6-(4-methoxybenzylamino)purine (8); n = 0-4 and solv = H2O, EtOH or MeOH. All the complexes have been fully characterized by elemental analysis, FTIR, UV-Vis and EPR spectroscopy, and by magnetic and conductivity measurements. Variable temperature (80-300 K) magnetic susceptibility data of 1-8 showed the presence of a strong antiferromagnetic exchange interaction between two Cu(II) (S= 1/2) atoms with J ranging from -150.0(1) to -160.3(2)cm(-1). The compound 6 center dot 4EtOH center dot H2O was structurally characterized by single crystal X-ray analysis. The Cu center dot center dot center dot Cu separation has been found to be 2.9092(8) angstrom. The antiradical activity of the prepared compounds was tested by in vitro SOD-mimic assay with IC50 in the range 8.67-41.45 mu M. The results of an in vivo antidiabetic activity assay were inconclusive and the glycaemia in pre-treated animals did not differ significantly from the positive control. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2010.06.007
• 作为产物：
  描述：

  4-甲氧基苄胺 、 6-氯嘌呤 在 三乙胺 作用下， 以 正丁醇 为溶剂， 反应 4.0h， 生成 6-(4-甲氧苄基氨基)嘌呤
  参考文献：
  名称：

  Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells

  摘要：

  To study the structure-activity relationships of aromatic cytokinins, the cytokinin activity at both the receptor and cellular levels, as well as CDK inhibitory and anticancer properties of 38 6-benzylaminopurine (BAP) derivatives were compared in various in vitro assays. The compounds were prepared by the condensation of 6-chloropurine with corresponding substituted benzylamines. The majority of synthesised derivatives exhibited high activity in all three of the cytokinin bioassays employed (tobacco callus, wheat senescence and Amaranthus bioassay). The highest activities were obtained in the senescence bioassay. For some compounds tested, significant differences of activity were found in the bioassays used, indicating that diverse recognition systems may operate and suggesting that it may be possible to modulate particular cytokinin-dependent processes with specific compounds. Position-specific steric and hydrophobic effects of different phenyl ring substituents on the variation of biological activity were confirmed. In contrast to their high activity in bioassays, the BAP derivatives were recognised with much lower sensitivity than trans-zeatin in both Arabidopsis thaliana AHK3 and AHK4 receptor assays. The compounds were also investigated for their effects on cyclin-dependent kinase 2 (CDK2) and for antiproliferative properties on cancer and normal cell lines. Several of the tested compounds showed stronger inhibitory activity and cytotoxicity than BAP. There was also a significant positive correlation of the inhibitory effects on human and plant CDKs with cell proliferation of cancer and cytokinin-dependent tobacco cells, respectively. This suggests that at least a part of the antiproliferative effect of the new cytokinins was due to the inhibition of CDK activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.09.004

文献信息

• [EN] COMPOUNDS FOR IMPROVING MRNA SPLICING<br/>[FR] COMPOSÉS POUR AMÉLIORER L'ÉPISSAGE DE L'ARNM
  申请人：GEN HOSPITAL CORP

  公开号：WO2016115434A1

  公开（公告）日：2016-07-21

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供了一些有助于改善细胞内mRNA剪接的化合物。本文提供的示例化合物有助于改善包含至少一个以核苷酸序列CAA结尾的外显子的基因的mRNA剪接。还提供了制备这些化合物的方法以及治疗中枢神经系统疾病的方法。
• [EN] CYCLOBUTAN-1,1 -DICARBOXYLATO COMPLEXES OF PLATINUM WITH N6-BENZYLADENINE DERIVATIVES, METHOD OF THEIR PREPARATION AND APPLICATION OF THESE COMPLEXES AS DRUGS IN ANTITUMOUR THERAPY<br/>[FR] COMPLEXES CYCLOBUTANE-1,1-DICARBOXYLATO DE PLATINE AVEC DES DÉRIVÉS DE N6-BENZYLADÉNINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR APPLICATION EN TANT QUE MÉDICAMENTS DANS UN TRAITEMENT ANTITUMORAL
  申请人：UNIV PALACKEHO

  公开号：WO2011029415A1

  公开（公告）日：2011-03-17

  Cyclobutane-1,1-dicarboxylato complexes of platinum in the oxidation state +II and their crystal-solvates including the structural motif I or having the general formula Il expressed by the structural formula [Pt(cbdc)(L)2] Il or the general formula III expressed by the structural formula [Pt(cbdc)(L)(L')] III, where the symbols L and L' stand for N6-benzyladenine derivatives of the general formula IV bound to the platinum atom of the basic motif V through any adenine nitrogen atom independently chosen from the N1, N3, N6, N7 or N9 atoms, depending on the substitution rate of the molecules IV, where the substituents R1, R2 a R3 are independently chosen from the group of: hydrogen atom, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, functional group and N-R'R" group, where R' and R" independently symbolize hydrogen atom, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and functional group.

  铂的氧化态为+II的环丁二酸-1,1-二羧酸配合物及其晶体溶剂包括结构基团I或具有由结构式[Pt(cbdc)(L)2] II表示的一般式Il或由结构式[Pt(cbdc)(L)(L')] III表示的一般式III，其中符号L和L'代表通式IV的N6-苄腺嘌呤衍生物，通过任何腺嘌呤氮原子独立选择自N1、N3、N6、N7或N9原子与基本基团V的铂原子结合，取决于分子IV的取代率，其中取代基R1、R2和R3独立选择自以下组中的: 氢原子、卤素、烷基、取代烷基、烯基、取代烯基、炔基、取代炔基、环烷基、取代环烷基、环杂烷基、取代环杂烷基、环烯基、取代环烯基、环杂烯基、取代环杂烯基、芳基、取代芳基、杂芳基、取代杂芳基、功能基团和N-R'R"基团，其中R'和R"独立表示氢原子、烷基、取代烷基、烯基、取代烯基、炔基、取代炔基、环烷基、取代环烷基、环杂烷基、取代环杂烷基、环烯基、取代环烯基、环杂烯基、取代环杂烯基、芳基、取代芳基、杂芳基、取代杂芳基和功能基团。
• Cross dehydrogenation coupling reaction of purine derivatives with thioethers
  作者：Xinjie Li、Peng Qi、Hongguang Du

  DOI：10.1039/d1ob02353e

  日期：——

  A metal-free cross-dehydrogenation coupling method was established to synthesize N9 alkylated purine derivatives. Using PhI(OAc)2 as the oxidant, versatile thioethers were successfully employed as alkylation reagents. Under the optimized conditions, a variety of alkylated purine derivatives and other aromatic N-heterocycles were obtained in moderate to good yields. The regioselectivity of this protocol

  建立了一种无金属交叉脱氢偶联方法合成N 9烷基化嘌呤衍生物。使用PhI(OAc) 2作为氧化剂，多功能硫醚被成功地用作烷基化试剂。在优化的条件下，以中等至良好的收率获得了多种烷基化嘌呤衍生物和其他芳香族N-杂环化合物。还研究了该协议的区域选择性，该协议涉及不对称硫醚与嘌呤衍生物的反应。
• Investigation of Ag(I) complexes involving 6-(benzylamino)purine derivatives
  作者：Tomáš Šilha、Michal Čajan、Zdeněk Trávníček

  DOI：10.1007/s00706-013-1078-4

  日期：2013.12

  complexes of the general composition [Ag(μ 2 -RBap)]·yH2O} n (y = 0 or 0.5), involving the deprotonated forms of the 6-(benzylamino)purine derivatives (RBap), was prepared. The compounds were characterized by elemental analysis (C, H, N), Raman and FT-IR spectroscopy, TG/DTA thermal analyses, and X-ray powder diffraction. On the basis of the fact that we were not able to prepare single crystals suitable

  摘要一系列银（I）的一般组合物的复合物[银（μ 2 - [R BAP）]· ÿ ħ 2 ö} Ñ（Ý  = 0或0.5），涉及6-（苄基氨基）的去质子化形式的嘌呤制备衍生物（R BAP）。通过元素分析（C，H，N），拉曼光谱和FT-IR光谱，TG / DTA热分析和X射线粉末衍射对化合物进行表征。基于我们无法制备适合X射线分析的单晶这一事实，尽管在不同条件下进行了许多尝试，但DFT计算被用于预测配合物的结构性质。计算结果暗示了 R BAP通过嘌呤部分的N1和N9原子与Ag（I）配体结合，从而形成涉及Ag（N1）（N9）供体的一维聚合物链结构。所选配合物的热分解产物通过扫描电子显微镜与能量色散X射线光谱相结合进行表征，并确定为平均粒径约为10μm的银聚集体。 图形概要
• Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
  申请人：Dolezal Karel

  公开号：US20050043328A1

  公开（公告）日：2005-02-24

  New heterocyclic derivatives based on N 6 -substituted adenine, having anticancer, mitotic, imunosuppressive and antisenescent propoerties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.

  基于N6-取代腺嘌呤的新杂环衍生物具有抗癌、有丝分裂、免疫抑制和抗衰老的性质，适用于植物、动物和人类细胞，并提供其制备方法。还包括含有这些衍生物作为活性化合物的药物组合物、化妆品制剂和生长调节剂，以及这些衍生物用于制备药物、化妆品制剂、生物技术过程、化妆品和农业的用途。